[go: up one dir, main page]

WO2009116801A3 - Caspase inhibitor prodrug - Google Patents

Caspase inhibitor prodrug Download PDF

Info

Publication number
WO2009116801A3
WO2009116801A3 PCT/KR2009/001368 KR2009001368W WO2009116801A3 WO 2009116801 A3 WO2009116801 A3 WO 2009116801A3 KR 2009001368 W KR2009001368 W KR 2009001368W WO 2009116801 A3 WO2009116801 A3 WO 2009116801A3
Authority
WO
WIPO (PCT)
Prior art keywords
caspase inhibitor
inhibitor prodrug
prodrug
caspase
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001368
Other languages
French (fr)
Other versions
WO2009116801A2 (en
Inventor
Hyun Ik Shin
Jae Hoon Lee
Yeong Soo Oh
Kyu Woong Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Publication of WO2009116801A2 publication Critical patent/WO2009116801A2/en
Publication of WO2009116801A3 publication Critical patent/WO2009116801A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to isoxazoline derivatives as a prodrug of caspase inhibitor, a process for preparing them, and a caspase inhibitor composition comprising the same.
PCT/KR2009/001368 2008-03-18 2009-03-18 Caspase inhibitor prodrug Ceased WO2009116801A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080025123A KR20090099886A (en) 2008-03-18 2008-03-18 Prodrugs of Caspase Inhibitors
KR10-2008-0025123 2008-03-18

Publications (2)

Publication Number Publication Date
WO2009116801A2 WO2009116801A2 (en) 2009-09-24
WO2009116801A3 true WO2009116801A3 (en) 2009-12-17

Family

ID=41091396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001368 Ceased WO2009116801A2 (en) 2008-03-18 2009-03-18 Caspase inhibitor prodrug

Country Status (2)

Country Link
KR (1) KR20090099886A (en)
WO (1) WO2009116801A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7362184B2 (en) * 2019-05-31 2023-10-17 エルジー・ケム・リミテッド Injectable compositions of caspase inhibitor prodrugs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021600A1 (en) * 1999-09-17 2001-03-29 Lg Chem Investment Ltd. Caspase inhibitor
WO2005021516A1 (en) * 2003-08-27 2005-03-10 Lg Life Sciences Ltd. Caspase inhibitors containing isoxazoline ring
WO2006090997A1 (en) * 2005-02-26 2006-08-31 Lg Life Sciences Ltd. Isoxazoline derivative and novel process for its preparation
WO2007015931A2 (en) * 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021600A1 (en) * 1999-09-17 2001-03-29 Lg Chem Investment Ltd. Caspase inhibitor
WO2005021516A1 (en) * 2003-08-27 2005-03-10 Lg Life Sciences Ltd. Caspase inhibitors containing isoxazoline ring
WO2006090997A1 (en) * 2005-02-26 2006-08-31 Lg Life Sciences Ltd. Isoxazoline derivative and novel process for its preparation
WO2007015931A2 (en) * 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs

Also Published As

Publication number Publication date
WO2009116801A2 (en) 2009-09-24
KR20090099886A (en) 2009-09-23

Similar Documents

Publication Publication Date Title
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
EP2457908B8 (en) Process for the Preparation of Compounds useful as inhibitors of SGLT
MY150542A (en) Cmet inhibitors
WO2010049454A3 (en) Antimicrobial composition from copepods
WO2008149345A3 (en) Tri-aryl compounds and compositions comprising the same
WO2007093627A3 (en) Biocidal composition
WO2009140624A3 (en) Glucokinase activators
UA110197C2 (en) To novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010063700A3 (en) Novel pyrazole-4 -n-alkoxycarboxamides as microbiocides
WO2010111626A3 (en) Poly (adp-ribose) polymerase (parp) inhibitors
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
WO2008127646A3 (en) Transaminase-based processes for preparation of pregabalin
AU2008246443A8 (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
WO2009127718A3 (en) Novel microbiocides
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2009126672A3 (en) 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and their use as fungicides
WO2008137134A3 (en) Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2008019030A8 (en) Modified azole compounds as antiinfective agents
WO2010039885A3 (en) Crystalline forms of dexlansoprazole
WO2008089005A3 (en) Renin inhibitors
WO2010059916A3 (en) Preparation of docetaxel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09722822

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09722822

Country of ref document: EP

Kind code of ref document: A2